Treatment of community-acquired methicillin-resistant Staphylococcus aureus infection [3]

Annals of Internal Medicine

Volumn 145, Issue 3, 2006, Pages 231-232

  De Almeida, Kleper N F ^a   Bush, Larry M ^a  

^a JFK Medical Center Atlantis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; GLYCOPEPTIDE; LINEZOLID; MINOCYCLINE; TIGECYCLINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; COMMUNICABLE DISEASE; MICROBIOLOGY; NOTE; PENICILLIN RESISTANCE;

ACETAMIDES; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; OXAZOLIDINONES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33746838940     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-3-200608010-00016     Document Type: Letter

References (5)

1. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309-17.
2. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260-6.
3. Kollef MH, Micek ST. Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? Curr Opin Infect Dis. 2006;19:161-8.
4. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390-8.
5. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22:593-8.